



STAFF REPORT

Global Market for Treatment and Diagnosis of Sexually Transmitted Diseases

September 2018

BCC Research Staff

Report Code: PHM005D

Additional segmentations and data sets available upon request. Email custom@bccresearch.com.

Table of Contents

Chapter 1: Introduction	1
Study Goals and Objectives.....	1
Reasons for Doing This Study.....	2
Scope of Report.....	2
Information Sources.....	3
Methodology.....	3
Geographic Breakdown.....	4
Analyst's Credentials.....	8
BCC Custom Research	8
Related BCC Research Reports.....	8
Chapter 2: Summary and Highlights	10
Chapter 3: Global Market Overview and Trends	14
Overview of Sexually Transmitted Diseases and Definitions.....	14
Sexually Transmitted Diseases and Pregnancy	15
Screening Programs and Guidelines	16
Mobile HIV Testing in Brazil	16
Benzathine Penicillin Drug Shortage.....	16
Trends in Global Transmission of STDs	17
Increasing Incidence of STDs	17
STD Awareness and Screening Services	18
Development of Test Kits with High Sensitivity for Low Resource Settings.....	20
Challenges	20
Underestimating the Risk of Contracting the Disease	20
Social Stigma Associated with STDs	21
Rising Incidence of Antibiotic Resistance	21
Lack of Prenatal Screening for STDs.....	22
Chapter 4: Disease Overview	24
Introduction	24
Chlamydia	27
Overview	27
Epidemiology.....	27
Diagnosis	30
Treatments	31
Genital Herpes	32
Overview	32
Epidemiology.....	32
Diagnosis	33
Treatments	34
Gonorrhea.....	34
Overview	34
Epidemiology.....	35
Diagnosis	37
Treatments	37

Hepatitis A, B and C.....	38
Overview	38
Epidemiology.....	40
Diagnosis	41
Treatments	43
Market Size.....	47
HIV/AIDS.....	49
Overview	49
Epidemiology.....	50
Diagnosis	53
Treatments	55
Market Size and Forecast	57
HPV.....	59
Overview	59
Diagnosis	59
Treatments	60
Syphilis	60
Overview	60
Epidemiology.....	61
Diagnosis	64
Treatments	64
Others	65
Overview	65
Market Analysis.....	68
Chapter 5: STD Diagnosis and Treatment Options.....	71
Introduction to STD Diagnostics, by Test Type	71
Enzyme Immunoassay (EIA) and ELISA.....	74
Polymerase Chain Reaction (PCR)	78
Rapid Diagnostics Tests (RDTs).....	79
Others	81
Introduction to Treatment by Drug Class	82
Antibiotics/Antibacterial	82
Antiviral/ Antiretrovirals	84
Others	86
Chapter 6: The North American Market Breakdown	90
Overview of North American Market	90
United States.....	94
Canada	102
Mexico	106
Chapter 7: The European Market Breakdown	109
Overview of the European Market	109
Chlamydia.....	109
United Kingdom	115
Germany	118
France	121
Spain.....	124
Italy	126
Rest of Europe.....	129

Chapter 8: The Asia-Pacific Market Breakdown	136
Overview of The Asia-Pacific Market.....	136
Market Analysis	136
Key Trends in STI Prevention	141
Legal Obstructions.....	141
Social Stigma and Discrimination	142
China	142
Prevention Programs.....	142
Legal and Punitive Barriers.....	143
Market Analysis	143
Japan	144
Chlamydia.....	144
Genital Herpes.....	145
Gonorrhea	146
Syphilis.....	146
Market Analysis	147
India	147
Launch of Hepcinat Plus for Hepatitis C in India	149
Aurobindo Pharma Files for Dolutegravir Generic.....	149
Market Analysis	149
South Korea.....	150
Market Analysis	151
Rest of Asia-Pacific	152
HIV/AIDS.....	152
Market Analysis	156
Chapter 9: Rest of World Market Breakdown	159
The Rest of World Overview	159
South American Market Overview.....	165
Middle East and Africa Overview	167
Chapter 10: Regulatory Structure	169
Overview of Regulations	169
United States.....	169
Europe.....	171
Japan	171
China	172
Overview of Pricing and Reimbursement	173
United States.....	173
Europe.....	177
Japan.....	178
Chapter 11: Pipeline Analysis.....	180
HIV Pipeline Overview.....	180
List of Drugs in HIV Pipeline	180
Hepatitis C Pipeline Overview	183
Several Drug Combinations Discontinued.....	183
Gonorrhea Pipeline Overview.....	184
Late-Stage Pipeline Molecules	184
Doravirine (MK-1439, DOR)	184
Drugs to Gain Marketing Authorization.....	185

Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide).....	185
Dolutegravir/Lamivudine (ViiV Healthcare)	185
Aikening (albuvirtide for injection) (Frontier Biotechnology Inc.)	185
Elpida (elsulfavirine) (Viriom, Inc.)	186
Isentress HD (Raltegravir) (Merck & Co., Inc.)	186
Chapter 12: Competitive Landscape and Key Developments	188
Market Structure Analysis.....	188
Patent Analysis.....	191
Key Developments	194
Mergers and Acquisitions.....	194
Development of Innovative Products/Novel Product Launches	194
Agreement, Collaboration and Partnerships	196
Chapter 13: Company Profiles	199
Appendix: Abbreviations.....	249
Abbreviations	249
About BCC Research.....	253
About BCC Research.....	254
BCC Membership	254

Additional segmentations and data sets available upon request. Email custom@bccresearch.com.

List of Tables

Summary Table A Global Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023 (\$ Millions)	11
Summary Table B Global Market for Sexually Transmitted Disease Diagnostics, by Test Type, Through 2023 (\$ Millions)	12
Table 1 Sexually Transmitted Diseases, by Different Pathogens	24
Table 2 Global Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023 (\$ Millions)	26
Table 3 Chlamydia Incidence, 2012-2017 (Per 100,000 Population).....	28
Table 4 Chlamydia Diagnostic Products, Brand Name and Manufacturer	30
Table 5 Drugs for Chlamydia Treatment.....	31
Table 6 Global HSV-1 Prevalence, Aged 0-49 years, 2012 (\$ Millions)	32
Table 7 Global HSV-1 Incidence, Aged 0-49 years, 2012 (\$ Millions)	33
Table 8 Genital Herpes Diagnostic Products, Brand Name and Manufacturer	33
Table 9 Gonorrhoea Epidemiology, 2012-2017 (Per 100,000 Population).....	35
Table 10 Gonorrhoea Diagnostic Products, Brand Name and Manufacturer.....	37
Table 11 Drug for Gonorrhoea Treatment.....	37
Table 12 Hepatitis A Incidence (Per 100,000 Population)	40
Table 13 Hepatitis B Incidence (Per 100,000 Population)	41
Table 14 Hepatitis C Incidence (Per 100,000 Population)	41
Table 15 Hepatitis B and C Diagnostic Products, Brand Name and Manufacturer.....	42
Table 16 Hepatitis B Medications by Brand Name, Generic Name, Manufacturer, Indication	44
Table 17 Hepatitis C Medications by Brand Name, Generic Name, Manufacturer, Indication	44
Table 18 Global Market for Hepatitis Therapeutics, by Region, Through 2023 (\$ Millions)	48
Table 19 HIV Prognosis	50
Table 20 HIV Incidence (Per 100,000 Population)	50
Table 21 HIV Incidence (Total Number of Cases).....	51
Table 22 HIV/AIDS Diagnostic Products, Brand Name and Manufacturer	54
Table 23 HIV Medications by Drug Class, Generic Name, Brand Name.....	56
Table 24 Global Market for HIV/AIDS Therapeutics, by Region, Through 2023 (\$ Millions)	58
Table 25 HPV Diagnostic Products, Brand Name and Manufacturer.....	60
Table 26 HPV Vaccines.....	60
Table 27 Syphilis Incidence (Per 100,000 Population).....	61
Table 28 Infectious Syphilis Incidence, by Country, 2012-2014 (Per 100,000 Population)	62
Table 29 Syphilis Diagnostic Products, Brand Name and Manufacturer	64
Table 30 Drug for Syphilis Treatment	64
Table 31 Trichomonas Vaginalis Diagnostic Assay, Brand Name, Type and Manufacturer.....	65
Table 32 Bacterial Vaginosis Diagnostic Products, Brand Name and Manufacturer	66
Table 33 Global Market for Other Therapeutics, by Region, Through 2023 (\$ Millions)	69
Table 34 Global Market for Sexually Transmitted Disease Diagnostics, by Region, Through 2023 (\$ Millions)	72
Table 35 Global Market for Sexually Transmitted Disease Diagnostics, by Test Type, Through 2023 (\$ Millions)	73
Table 36 Antibacterial Drugs for STD.....	83
Table 37 Global Market for Antibiotics, by Region, Through 2023 (\$ Millions)	84
Table 38 Global Market for Antiviral/Antiretroviral drugs, by Region, Through 2023 (\$ Millions).....	85
Table 39 Global Market for Other Drug Class, by Region, Through 2023 (\$ Millions).....	87
Table 40 North American Estimated HBsAG Seroprevalence, 2016.....	90

Table 41 North American Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023 (\$ Millions).....	91
Table 42 North American Market for Sexually Transmitted Disease Therapeutics, by Drug Class, Through 2023 (\$ Millions)	92
Table 43 United States Historic and Current Chancroid Trend, Incidence, 1990-2016 (Per 100,000 Population).....	99
Table 44 European Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023 (\$ Millions)	111
Table 45 European Market for Sexually Transmitted Disease Therapeutics, by Drug Class, Through 2023 (\$ Millions)	113
Table 46 Asia-Pacific Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023 (\$ Millions)	137
Table 47 Asia-Pacific Market for Sexually Transmitted Disease Therapeutics, by Drug Class, Through 2023 (\$ Millions)	139
Table 48 South American, Middle East and Africa HIV/AIDS Epidemiology, 2016	159
Table 49 South American, Middle East & Africa Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023 (\$ Millions)	162
Table 50 South American, Middle East & Africa Market for Sexually Transmitted Disease Therapeutics by Drug Class, Through 2023 (\$ Millions)	163
Table 51 South American Estimated HBsAG Seroprevalence, 2016.....	166
Table 52 Latin America Estimated HCV Prevalence, 2016 (%).....	166
Table 53 Latin America Estimated HCV Prevalence, 2016 (\$ Millions).....	167
Table 54 Preventive Health Services for Adults Covered by Private Plans Without Cost Sharing.....	176
Table 55 Preventive Health Services for Children Covered by Private Plans Without Cost Sharing	177
Table 56 HIV Pipeline, 2018	180
Table 57 Gonorrhea Pipeline, 2018	184
Table 58 Gilead Sciences, Inc. Leading Products Revenue, 2015-2017 (\$ Millions)	188
Table 59 GlaxoSmithKline Plc. Leading Products Revenue, 2015-2017 (\$ Millions).....	189
Table 60 Merck & Co., Inc. Leading Products Revenue, 2015-2017 (\$ Millions)	190
Table 61 Leading Products Revenue, by Company, 2015-2017 (\$ Millions).....	190
Table 62 Global Market Share Analysis for Sexually Transmitted Disease Therapeutics, by Company (%)	191
Table 63 Key Patents, Manufacturer, Indication, Approval Date and Expiration	192
Table 64 Abbott Laboratories Marketed Products	199
Table 65 Abbott Laboratories Marketed Products, Diagnostics.....	200
Table 66 Abbott Laboratories Net Revenue, 2015-2017 (\$ Millions)	201
Table 67 AbbVie Inc. Marketed Products	203
Table 68 AbbVie Inc. Net Revenue, 2015-2017 (\$ Millions)	203
Table 69 Agilent Technologies, Inc. Net Revenue, 2015-2017 (\$ Millions)	205
Table 70 Becton, Dickinson and Company Marketed Products.....	207
Table 71 Biomerieux, Inc. Marketed Products.....	210
Table 72 Bio-Rad Laboratories Marketed Products.....	211
Table 73 Boehringer Ingelheim GmbH, Net Revenue, 2014-2016 (\$ Millions)	212
Table 74 Bristol-Myers Squibb Company Marketed Products.....	215
Table 75 Bristol-Myers Squibb Company Net Revenue, 2014–2016 (\$ Millions).....	215
Table 76 Gilead Science Inc. Marketed Products.....	217
Table 77 Gilead Sciences Inc. Net Revenue, 2014-2016 (\$ Millions).....	219
Table 78 GlaxoSmithKline PLC Marketed Products	221
Table 79 ViiV Healthcare Group of Companies Marketed Products.....	222
Table 80 GlaxoSmithKline PLC Net Revenue, 2014-2016 (\$ Millions)	223
Table 81 Hoffmann-La Roche Inc. Marketed Products	225

Table 82 Hoffmann-La Roche Inc. Net Revenue, 2015-2017 (\$ Millions)	226
Table 83 Hologic, Inc. Marketed Products	229
Table 84 Hologic Inc. Net Revenue, 2015-2017 (\$ Millions)	229
Table 85 Janssen Pharmaceuticals, Inc. Marketed Products	230
Table 86 Johnson & Johnson Inc. Net Revenue, 2014-2016 (\$ Millions)	231
Table 87 Merck & Co. Inc. Marketed Products	233
Table 88 Merck & Co. Inc. Net Revenue, 2014-2016 (\$ Millions)	234
Table 89 Meridian Life Science, Inc. Marketed Products	236
Table 90 Novartis AG Marketed Products	236
Table 91 Novartis AG Net Revenue, 2014-2016 (\$ Millions)	237
Table 92 Pfizer Inc. Marketed Products by Indication	239
Table 93 Pfizer Inc. Net Revenue, 2015-2017 (\$ Millions)	239
Table 94 Qiagen N.V Marketed Products	242
Table 95 Qiagen N.V. Net Revenue, 2015-2017 (\$ Millions)	243
Table 96 Quidel Corp Marketed Products	245
Table 97 Thermo Fisher Scientific, Inc. Marketed Products	246
Table 98 Abbreviations Used in Sexually Transmitted Disease Therapeutics and Diagnostics Market..	249

List of Figures

Summary Figure A Global Market for Sexually Transmitted Disease Therapeutics, by Disease Area, 2017-2023 (\$ Millions)	11
Summary Figure B Global Market for Sexually Transmitted Disease Diagnostics, by Test Type, 2017-2023 (\$ Millions)	12
Figure 1 Estimated Deaths Owing to Infectious and Parasitic Diseases, 2016 (%)	17
Figure 2 Global Historic and Current Gonorrhea Trend, Incidence, in Men, 2012-2014 (Per 100,000 Population).....	18
Figure 3 United States Funding Trend, HIV/AIDS, Viral Hepatitis, STIs, and TB, 2014-2017 (\$ Millions) ..	19
Figure 4 Global Market for Sexually Transmitted Disease Therapeutics, 2017-2023 (\$ Millions).....	25
Figure 5 Global Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2018 (%)	26
Figure 6 Global Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2023 (%)	27
Figure 7 Global Historic and Current Chlamydia Trend, Incidence, Women, 2012-2014 (Per 100,000 Population).....	29
Figure 8 Global Historic and Current Chlamydia Trend, Incidence, Men, 2012-2014 (Per 100,000 Population).....	29
Figure 9 Global Historic and Current Gonorrhea Trend, Incidence, Men, 2012-2014 (Per 100,000 Population).....	36
Figure 10 Global Historic and Current Gonorrhea Trend, Incidence, Women, 2012-2014 (Per 100,000 Population).....	36
Figure 11 Hepatitis Timeline, 1990-2004	38
Figure 12 Hepatitis Timeline, 2011-2015	39
Figure 13 Hepatitis Timeline, 2015-2017	39
Figure 14 Global Market for Hepatitis Therapeutics, 2017-2023 (\$ Millions)	48
Figure 15 Global Market for Hepatitis, by Region, 2017-2023 (\$ Millions)	49
Figure 16 Global Historic and Current HIV Trend, Prevalence, 2012-2016 (\$ Millions)	52
Figure 17 Estimated HIV Regional Prevalence, 2016 (Total: 36.7 Millions)	52
Figure 18 Estimated HIV Regional Incidence, 2016 (Total: 1.8 Millions)	53
Figure 19 Global Market for HIV/AIDS Therapeutics, 2017-2023 (\$ Millions).....	58
Figure 20 Global Market for HIV/AIDS Therapeutics, by Region, 2017-2023 (\$ Millions)	59
Figure 21 United States Syphilis Incidence Among Newborns, 2014-2016 (Number of Cases)	62
Figure 22 Global Historic and Current Infectious Syphilis Trend, Incidence, Men, 2012-2014 (Per 100,000 Population).....	63
Figure 23 Global Historic and Current Infectious Syphilis Trend, Incidence, Men, 2012-2014 (Per 100,000 Population).....	63
Figure 24 Global Market for Other Therapeutics, 2017-2023 (\$ Millions)	68
Figure 25 Global Market for Other Therapeutics, by Region, 2017-2023 (\$ Millions)	69
Figure 26 Global Market for Sexually Transmitted Disease Diagnostics, 2017-2023 (\$ Millions)	71
Figure 27 Global Market for Sexually Transmitted Disease Diagnostics, by Region, 2017-2023 (\$ Millions)	72
Figure 28 Global Market Share for Sexually Transmitted Disease Diagnostics, by Test Type, 2018 (%) ..	73
Figure 29 Global Market Share for Sexually Transmitted Disease Diagnostics, by Test Type, 2023 (%) ..	74
Figure 30 Global Market for Enzyme Immunoassay (EIA) and ELISA Diagnostics, 2017-2023 (\$ Millions).....	78
Figure 31 Global Market for PCR Diagnostics, 2017-2023 (\$ Millions).....	79
Figure 32 Global Market for Rapid Diagnostic Tests (RDTs) Diagnostics, 2017-2023 (\$ Millions).....	80
Figure 33 Global Market for Other Diagnostics, 2017-2023 (\$ Millions).....	82

Figure 34 Global Market for Antibiotic Drugs, 2017-2023 (\$ Millions).....	83
Figure 35 Global Market for Antibiotic Drugs, by Region, 2017-2023 (\$ Millions).....	84
Figure 36 Global Market for Antiviral/Antiretroviral Drugs, 2017-2023 (\$ Millions)	85
Figure 37 Global Market for Antiviral/Antiretroviral Drugs, by Region, 2017-2023 (\$ Millions)	86
Figure 38 Global Market for Other Drug Class, 2017-2023 (\$ Millions)	87
Figure 39 Global Market for Other Drug Class, by Region, 2017-2023 (\$ Millions).....	88
Figure 40 North American Market for Sexually Transmitted Therapeutics, 2017-2023 (\$ Millions)	90
Figure 41 North American Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2018 (%)	91
Figure 42 North American Market for Sexually Transmitted Disease Therapeutics, by Disease Area, 2023 (%)	92
Figure 43 North American Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2018 (%)	93
Figure 44 North American Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2023 (%)	93
Figure 45 North American Market for Sexually Transmitted Disease Therapeutics, by Country, 2017-2023 (\$ Millions)	94
Figure 46 United States Sexually Transmitted Diseases Incidence, 2016 (Number of Cases)	95
Figure 47 United States Sexually Transmitted Infections, by Sex, 2016 (Per 100,000 Population).....	96
Figure 48 United States Historic and Current Syphilis Trend, Incidence, 1990-2016 (Per 100,000 Population).....	97
Figure 49 United States Historic and Current Chlamydia Trend, Incidence, 1990-2016 (Per 100,000 Population).....	98
Figure 50 United States Historic and Current Gonorrhea Trend, Incidence, 1990-2016 (Per 100,000 Population).....	98
Figure 51 United States Historic and Current Hepatitis A Trend, Incidence, 2012-2016 (Per 100,000 Population).....	99
Figure 52 United States Historic and Current Acute Hepatitis B Trend, Incidence, 2012-2016 (Per 100,000 Population).....	100
Figure 53 United States Historic and Current Hepatitis C Trend, Incidence, 2012-2016 (Per 100,000 Population).....	100
Figure 54 United States Historic and Current HIV Trend, Incidence, 2011-2016 (Total Number of Cases)	101
Figure 55 United States Market for Sexually Transmitted Disease Therapeutics, 2018-2023 (\$ Millions)	101
Figure 56 Canadian Sexually Transmitted Infections, by Sex, 2014 (Per 100,000 Population)	102
Figure 57 Canadian Historic and Current Chlamydia Trend, Incidence, 2005-2014 (Per 100,000 Population).....	103
Figure 58 Canadian Historic and Current Gonorrhea Trend, Incidence, by Sex, 2005-2014 (Per 100,000 Population).....	103
Figure 59 Canadian Historic and Current Infectious Syphilis Trend, Incidence, 2005-2014 (Per 100,000 Population).....	104
Figure 60 Canadian Historic and Current Congenital Syphilis Trend, Incidence, 2005-2014 (Per 100,000 Population).....	105
Figure 61 Canadian Market for Sexually Transmitted Disease Therapeutics, 2017-2023 (\$ Millions)....	106
Figure 62 Mexican Market for Sexually Transmitted Disease Therapeutics, 2017-2023 (\$ Millions)	107
Figure 63 European Historic and Current Chlamydia Trend, Incidence, 2012-2015 (Per 100,000 Population).....	109
Figure 64 European Historic and Current AIDS Trend, Incidence, 2007-2011 (Total Cases)	110
Figure 65 European Market for Sexually Transmitted Disease Therapeutics, 2017-2023 (\$ Millions) ...	111

Figure 66 European Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2018 (%)	112
Figure 67 European Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2023 (%)	112
Figure 68 European Market for Sexually Transmitted Disease Therapeutics, by Drug Class, 2018 (%) ..	113
Figure 69 European Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2023 (%)	114
Figure 70 European Market for Sexually Transmitted Disease Therapeutics, by Country, 2017-2023 (\$ Millions)	115
Figure 71 United Kingdom HIV Incidence, Gay and Bisexual Men, 2015 and 2016 (Total Cases)	116
Figure 72 United Kingdom Historic and Current Gonorrhea Trend, Incidence, 2011-2015 (Number of Cases)	116
Figure 73 United Kingdom Historic and Current Hepatitis B Trend, Incidence, 2012-2016 (Number of Cases)	117
Figure 74 United Kingdom Historic and Current Hepatitis C Trend, Incidence, 2012-2016 (Number of Cases)	117
Figure 75 United Kingdom Market for Sexually Transmitted Disease Therapeutics, 2018-2023 (\$ Millions)	118
Figure 76 German Historic and Current Hepatitis B Trend, Incidence, 2012-2016 (Number of Cases) ..	119
Figure 77 German Historic and Current Hepatitis C Trend, Incidence, 2012-2016 (Number of Cases) ..	120
Figure 78 German Market for Sexually Transmitted Disease Therapeutics, 2018-2023 (\$ Millions)	121
Figure 79 French Historic and Current Chlamydia Trend, Incidence, 2011-2015 (Number of Cases)	122
Figure 80 French Historic and Current Gonorrhea Trend, Incidence, 2011-2015 (Number of Cases)	122
Figure 81 French Historic and Current Hepatitis B Trend, Incidence, 2012-2016 (Number of Cases)	123
Figure 82 French Market for Sexually Transmitted Disease Therapeutics, 2017-2023 (\$ Millions)	123
Figure 83 Spain Historic and Current Chlamydia Trend, Incidence, 2011-2015 (Number of Cases)	124
Figure 84 Spain Historic and Current Gonorrhea Trend, Incidence, 2011-2015 (Number of Cases)	125
Figure 85 Spain Historic and Current Hepatitis B Trend, Incidence, 2012-2016 (Number of Cases)	125
Figure 86 Spain Market for Sexually Transmitted Disease Therapeutics, 2017-2023 (\$ Millions)	126
Figure 87 Italian Historic and Current Chlamydia Trend, Incidence, 2011-2015 (Number of Cases)	126
Figure 88 Italian Historic and Current Gonorrhea Trend, Incidence, 2011-2015 (Number of Cases)	127
Figure 89 Italian Historic and Current Hepatitis B Trend, Incidence, 2012-2016 (Number of Cases)	127
Figure 90 Italian Historic and Current Hepatitis C Trend, Incidence, 2012-2016 (Number of Cases)	128
Figure 91 Italian Market for Sexually Transmitted Disease Therapeutics, 2017-2023 (\$ Millions)	128
Figure 92 Denmark Historic and Current Chlamydia Trend, Incidence, 2011-2015 (Number of Cases) ..	129
Figure 93 The Netherlands Historic and Current Chlamydia Trend, Incidence, 2011-2015 (Number of Cases)	130
Figure 94 Denmark Historic and Current Gonorrhea Trend, Incidence, 2011-2016 (Number of Cases) ..	131
Figure 95 Ireland Historic and Current Gonorrhea Trend, Incidence, 2011-2015 (Number of Cases)	131
Figure 96 The Netherlands Historic and Current Hepatitis B Trend, Incidence, 2012-2016 (Number of Cases)	132
Figure 97 Sweden Historic and Current Hepatitis B Trend, Incidence, 2012-2016 (Number of Cases) ...	132
Figure 98 Sweden Historic and Current Hepatitis C Trend, Incidence, 2012-2016 (Number of Cases) ...	133
Figure 99 Poland Historic and Current Hepatitis C Trend, Incidence, 2012-2016 (Number of Cases)	133
Figure 100 Rest of Europe Market for Sexually Transmitted Disease Therapeutics, 2017-2023 (\$ Millions)	134
Figure 101 Asia-Pacific Market for Sexually Transmitted Disease Therapeutics, 2017-2023 (\$ Millions)	137
Figure 102 Asia-Pacific Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2018 (%)	138

Figure 103 Asia-Pacific Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2023 (%)	138
Figure 104 Asia-Pacific Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2018 (%)	139
Figure 105 Asia-Pacific Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2023 (%)	140
Figure 106 Asia-Pacific Market for Sexually Transmitted Disease Therapeutics, by Country, 2017-2023 (\$ Millions)	141
Figure 107 Chinese Market for Sexually Transmitted Disease Therapeutics, 2017-2023 (\$ Millions)	143
Figure 108 Japanese Historic and Current HIV/AIDS Infections, Incidence, 2001-2016 (Total Cases)	144
Figure 109 Japanese Historic and Current Chlamydia Trend, Incidence, 2000-2014 (Total Cases).....	145
Figure 110 Japanese Historic and Current Genital Herpes Trend, Incidence, 2000-2014 (Total Cases)..	145
Figure 111 Japanese Historic and Current Gonorrhoea Trend, Incidence, 2000-2014 (Total Cases)	146
Figure 112 Japanese Historic and Current Syphilis Trend, Incidence, 2008-2014 (Per 100,000 Population)	146
Figure 113 Japanese Market for Sexually Transmitted Disease Therapeutics, 2017-2023 (\$ Millions) ..	147
Figure 114 Indian Historic and Current HIV Trend, Incidence, 2005-2016 (Total Cases)	148
Figure 115 Indian Historic and Current HIV Trend, Prevalence, 2005-2016 (Total Cases)	148
Figure 116 Indian Historic and Current AIDS, Mortality, 2005-2016 (Total Cases).....	149
Figure 117 Indian Market for Sexually Transmitted Disease Therapeutics, 2017-2023 (\$ Millions).....	150
Figure 118 South Korean Historic and Current HIV/AIDS Infections, Incidence, 2001-2016 (Total Cases)	151
Figure 119 South Korean Market for Sexually Transmitted Disease Therapeutics, 2017-2023 (\$ Millions)	152
Figure 120 Australia Historic and Current HIV Trend, Incidence, 2012-2014 (Total Cases)	153
Figure 121 Australia Mode of HIV Transmission, 2015 (%).....	154
Figure 122 Australia Historic and Current Hepatitis C Trend, Incidence, 2007-2014 (Total Cases).....	154
Figure 123 Australia Historic and Current Hepatitis B Trend, Incidence, 2007-2014 (Total Cases)	155
Figure 124 Singapore Historic and Current HIV/AIDS Infections, Incidence, 2001-2015 (Total Cases)...	155
Figure 125 Republic of Korea Historic and Current HIV/AIDS Infections, Incidence, 2001-2016 (Total Number of Cases).....	156
Figure 126 Rest of Asia-Pacific Market for Sexually Transmitted Disease Therapeutics, 2017-2023 (\$ Millions)	157
Figure 127 HBV Prevalence, by Region, 2015 (\$ Millions)	160
Figure 128 HCV Infection, by Region, 2015 (Per 100,000 Population)	160
Figure 129 HCV Prevalence, by Region, 2015 (\$ Millions)	161
Figure 130 South American, Middle East & Africa Market for Sexually Transmitted Disease Therapeutics, 2017-2023 (\$ Millions)	161
Figure 131 South American, Middle East & Africa Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2018 (%).....	162
Figure 132 South American, Middle East & Africa Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2023 (%).....	163
Figure 133 South American, Middle East & Africa Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2018 (%).....	164
Figure 134 South American, Middle East & Africa Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2023 (%).....	164
Figure 135 Gilead Sciences, Inc. Antiviral Sales, 2015-2017 (\$ Billions)	189
Figure 136 Abbott Laboratories, Revenue Share, by Region, 2017 (%)	201
Figure 137 Abbott Laboratories Revenue Share, by Business Segment, 2017 (%)	202
Figure 138 AbbVie Inc. Revenue Share, by Region, 2016 (%)	204
Figure 139 Agilent Technologies, Inc. Revenue Share, by Region, 2017 (%)	205

Figure 140 Agilent Technologies, Inc. Revenue Share, by Business Segment, 2017 (%)	206
Figure 141 Becton, Dickinson and Company Financial Performance, 2013-2017 (\$ Millions)	208
Figure 142 Becton, Dickinson and Company Revenue Share, by Business Segment, 2017 (%)	208
Figure 143 Becton, Dickinson and Company Revenue Share, by Region, 2017 (%)	209
Figure 144 Boehringer Ingelheim GmbH Revenue Share, by Region, 2016 (%)	212
Figure 145 Boehringer Ingelheim GmbH Revenue Share, by Business Segment, 2016 (%)	213
Figure 146 Boehringer Ingelheim GmbH R&D Expenditure, 2014-2016 (\$ Millions)	214
Figure 147 Bristol-Myers Squibb Company Revenue Share, by Region, 2016 (%)	216
Figure 148 Bristol-Myers Squibb Company Revenue Share, by Business Segment, 2016 (%)	216
Figure 149 Gilead Sciences Inc. Revenue Share, by Business Segment, 2016	220
Figure 150 Gilead Sciences Inc. Revenue Share, by Region, 2016	220
Figure 151 GlaxoSmithKline PLC Revenue Share by Business Segment, 2016	224
Figure 152 GlaxoSmithKline PLC Revenue Share, by Region, 2016	224
Figure 153 Hoffmann-La Roche Inc. Revenue Share, by Segment, 2017 (%)	227
Figure 154 Hoffmann-La Roche Inc. Revenue Share, by Region, 2017 (%)	227
Figure 155 Johnson & Johnson Inc. Revenue Share, by Business Segment, 2016	232
Figure 156 Johnson & Johnson Inc. Revenue Share, by Region, 2016	232
Figure 157 Merck & Co. Inc. Revenue Share, by Business Segment, 2016	234
Figure 158 Merck & Co. Inc. Revenue Share, by Region, 2016	235
Figure 159 Novartis AG Revenue Share, by Region, 2016 (%)	237
Figure 160 Novartis AG Revenue Share, by Business Segment, 2016 (%)	238
Figure 161 Pfizer Inc. Revenue Share, by Region, 2016 (%)	240
Figure 162 Pfizer Inc. Revenue Share by Business Segment, 2016 (%)	240
Figure 163 Qiagen N.V Revenue Share, by Region, 2017 (%)	243
Figure 164 Qiagen N.V Revenue Share, by Business Segment, 2017 (%)	244
Figure 165 Thermo Fisher Scientific, Inc. Revenue Share, by Region, 2016 (%)	247
Figure 166 Thermo Fisher Scientific, Inc. Revenue Share, by Business Segment, 2016 (%)	247



About BCC Research

About BCC Research

With our unparalleled 45-year history, BCC Research provides comprehensive analysis of global market sizing, forecasting and industry intelligence, covering markets where advances in science and technology are improving the quality, standard and sustainability of businesses, economies and lives.

BCC Membership

From market sizing and forecasts, to opportunity assessments and competitive analyses, our ever-expanding library gives you the data, insights and intelligence required to ensure your project is a success. Members benefit from ongoing, unlimited access to the category or collections of their choice, and most membership packages pay for themselves within two to three reports being accessed.

Did you buy this report? You may qualify to apply your purchase price towards a full membership. Call 866/285-7215 or email info@bccresearch.com to request a demo.

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

ISBN: 978-1-62296-850-3
September 2018